Healthpeak Properties
DOC
$18.52
-0.75%
Healthpeak Properties, Inc. is a real estate investment trust that owns and operates a diversified healthcare real estate portfolio of approximately 700 in-place properties, primarily concentrated in medical office buildings and life science assets, alongside a smaller collection of senior housing, hospital, and skilled nursing/post-acute care facilities. As one of the largest dedicated healthcare REITs in the United States, Healthpeak occupies a distinct position as a scaled, diversified landlord whose tenant base is heavily tied to health systems, physician groups, and life science research organizations, differentiating it from single-segment peers focused purely on senior housing or medical office. The current investor narrative centers on the durability of its outpatient medical and lab leasing demand against a challenging life science funding backdrop, with the stock having rallied sharply from its spring lows before giving back ground into early autumn. Recent attention has also focused on the company's capital recycling activity, including a large first-quarter acquisition and debt repayment program, as well as its elevated dividend yield, which continues to attract income-oriented investors even as earnings quality and payout sustainability remain points of debate.…
DOC
Healthpeak Properties
$18.52
Investment Opinion: Should I buy DOC Today?
Based on the synthesis of data, DOC warrants a Hold rating. The core thesis is that while the stock offers an attractive 7.59% dividend yield and trades at a discount to analyst targets (average $22.95, implying 17.7% upside), recent negative momentum, high valuation multiples, and analyst downgrades suggest limited near-term catalysts. The consensus recommendation is 'buy' with a mean of 2.41, but the wide target range and recent moves to Equal Weight indicate caution. Supporting evidence includes a 7.12% year-over-year revenue growth in Q1 2026, a robust EBITDA margin of 76.6%, and a payout ratio of only 11.9%, which supports dividend safety. However, the trailing PE of 160.8x and EV/EBITDA of 14.31x are elevated, and the stock's 10.96% three-month decline reflects waning investor confidence. The 7.59% dividend yield is a key attraction, but it comes with the risk of capital depreciation if earnings fail to recover. The biggest risks that could invalidate the thesis include a continued rise in interest rates, which would increase borrowing costs and pressure REIT valuations, and a slowdown in life science leasing demand, which could impair revenue growth. Additionally, if GAAP earnings do not improve, the stock could face further multiple compression. The rating would upgrade to Buy if the stock price stabilizes above $20 and leasing spreads accelerate, or downgrade to Sell if revenue growth decelerates below 5% or if the dividend coverage ratio deteriorates. Relative to its history, DOC's price-to-book of 1.49x is near the lower end of its multi-year range, suggesting it is not expensive on an asset basis, but the earnings-based metrics indicate overvaluation. Overall, DOC appears fairly valued to slightly overvalued, with the dividend providing a cushion but limited capital appreciation potential in the near term.
Sign up to view all
DOC 12-Month Price Forecast
DOC presents a balanced risk-reward profile, with the high dividend yield and discounted price-to-book ratio offering downside support, but the premium earnings multiples and recent negative momentum limiting upside. The base case is most likely, with the stock expected to trade in the $21-24 range as earnings gradually recover. However, the wide analyst target range and recent downgrades suggest uncertainty. I would upgrade to bullish if the stock breaks above $22.95 with strong volume and leasing spreads accelerate, or downgrade to bearish if it falls below $18 on deteriorating fundamentals.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Healthpeak Properties's 12-month outlook, with a consensus price target around $22.95 and implied upside of +23.9% versus the current price.
Average Target
$22.95
0 analysts
Implied Upside
+23.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$17 - $29
Analyst target range
Coverage on Healthpeak is robust, with 19 analysts contributing to a consensus recommendation of "buy" and a recommendation mean of 2.41 on a scale where lower is more bullish. The average price target of $22.95 implies approximately 17.7% upside from the current $19.49, a meaningful expected return that suggests the sell-side views the recent pullback as an opportunity rather than a deterioration in fundamentals. The consensus leans moderately bullish, but the recommendation mean of 2.41 indicates a substantial cohort of neutral or hold-rated analysts, consistent with the recent institutional actions showing several firms maintaining Equal Weight or Neutral stances. The target range spans $17.00 to $29.00, a wide $12 spread that signals significant disagreement about the company's trajectory. The high target of $29.00 implies roughly 48.8% upside and would require either multiple expansion toward historical peaks, accelerating life science leasing demand, or successful capital deployment at attractive yields. The low target of $17.00, about 12.8% below the current price, prices in margin compression, weaker-than-expected leasing spreads, or a higher-for-longer interest rate environment pressuring REIT valuations. Recent institutional ratings show a mildly cautious tilt, with Barclays downgrading to Equal Weight from Overweight in July 2026 and Morgan Stanley moving to Equal Weight from Overweight in June 2026, while Mizuho and BMO Capital maintained Outperform ratings. This pattern of downgrades to neutral territory, combined with the wide target spread, suggests analysts are increasingly divided on whether the recovery can be sustained, and the stock's recent underperformance relative to the broader market reflects that uncertainty.
Drowning in data?
Find the real signal!
Bulls vs Bears: DOC Investment Factors
The bull case for DOC rests on its high dividend yield, strong EBITDA margin, and analyst consensus for upside, while the bear case highlights extreme valuation multiples, recent negative momentum, and high leverage. Currently, the bear evidence appears stronger due to the stock's 10.96% three-month decline, underperformance versus the market, and analyst downgrades, despite the attractive yield. The most critical tension is whether DOC can accelerate earnings growth to justify its premium valuation; if GAAP earnings fail to recover, the stock could face further downside. Conversely, if leasing demand in life science and medical office segments strengthens, the stock could re-rate toward analyst targets.
Bullish
- Attractive 7.59% Dividend Yield: DOC offers a dividend yield of 7.59%, well above the broader real estate sector average, providing substantial income for yield-focused investors. The payout ratio is only 11.9% of trailing earnings, suggesting the dividend is well-covered by cash flow and has room to grow.
- Analyst Consensus Buy with 17.7% Upside: 19 analysts rate DOC a 'buy' with an average target price of $22.95, implying 17.7% upside from the current $19.49. The high target of $29.00 suggests potential for 48.8% gains if operational momentum accelerates.
- Strong EBITDA Margin of 76.6%: Q1 2026 EBITDA was $576.9 million on revenue of $753.0 million, a 76.6% margin, highlighting the cash-generative nature of DOC's property portfolio. This robust profitability supports ongoing dividend payments and debt servicing.
- Revenue Growth of 7.1% YoY: Q1 2026 revenue grew 7.12% year-over-year to $753.0 million, driven by steady demand in outpatient medical and lab segments. This growth, while modest, outpaces inflation and supports stable cash flows.
Bearish
- Extreme Valuation at 160.8x Trailing PE: DOC trades at a trailing PE of 160.8x and a forward PE of 139.2x, far above any reasonable earnings-based benchmark. This reflects depressed GAAP earnings and implies the market expects a slow, uncertain earnings recovery.
- Negative Price Momentum Over 3 Months: The stock is down 10.96% over the past three months and 7.32% over one month, significantly underperforming SPY by 14.30 and 7.91 percentage points, respectively. This recent weakness suggests waning investor confidence and potential for further declines.
- High Leverage with Debt-to-Equity of 1.39x: DOC carries a debt-to-equity ratio of 1.39x, which is substantial for a REIT and increases financial risk, especially in a higher-for-longer interest rate environment. Interest expense of $87.3 million in Q1 2026 consumes a significant portion of operating income.
- Low ROE of 0.95% and ROA of 1.51%: Return on equity is just 0.95% and return on assets 1.51%, indicating poor profitability relative to the capital employed. This low return profile may limit the company's ability to grow earnings and justify its premium valuation.
DOC Technical Analysis
Healthpeak is in a broad recovery phase that has stalled over the past quarter. The stock is up 1.62% over the trailing twelve months and 20.31% year-to-date, but at $19.49 it sits only about 49.5% of the way through its 52-week range of $15.70 to $22.95, having peaked at $22.82 in late July before retreating. That mid-range positioning, combined with a 17.98% six-month gain, suggests the recovery is intact but the stock has surrendered a meaningful portion of its momentum rather than pressing to new highs. Recent momentum has clearly decelerated and turned negative: the shares are down 7.32% over the past month and 10.96% over three months, a sharp divergence from the positive one-year and year-to-date trends. Relative strength confirms the underperformance, with DOC lagging SPY by 7.91 percentage points over one month and 14.30 points over three months, even though it outperformed by 7.45 points year-to-date. This pattern of strong early-year gains followed by a three-month slide points to profit-taking and mean reversion rather than a full trend reversal, though the persistent selling pressure into October warrants caution. Key support rests at the 52-week low of $15.70, roughly 19.4% below the current price, while resistance sits at the 52-week high of $22.95, about 17.7% above. A breakout above $22.95 would signal renewed institutional accumulation and validate the recovery, whereas a breakdown below $15.70 would confirm a deeper downtrend and likely trigger momentum-driven selling. With a beta of 0.989, DOC moves roughly in line with the broader market, so its 18.53% maximum drawdown reflects stock-specific and sector-specific pressures rather than elevated systematic volatility, meaning position sizing can be managed closer to market-neutral assumptions.
Beta
0.99
0.99x market volatility
Max Drawdown
-18.8%
Largest decline past year
52-Week Range
$16-$23
Price range past year
Annual Return
-1.8%
Cumulative gain past year
| Period | DOC Return | S&P 500 |
|---|---|---|
| 1m | -9.7% | +1.0% |
| 3m | -14.5% | +2.5% |
| 6m | +10.6% | +13.9% |
| 1y | -1.8% | +15.0% |
| ytd | +14.3% | +13.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DOC Fundamental Analysis
Healthpeak's revenue trajectory is modestly growing but decelerating at the margin. First-quarter 2026 revenue came in at $752.95 million, up 7.12% year-over-year from $702.89 million in Q1 2025, continuing a steady climb from $719.40 million in Q4 2025 and $705.87 million in Q3 2025. Segment data shows outpatient medical buildings contributing the largest share at $318.22 million, followed by lab at $212.81 million and senior housing at $200.35 million, meaning the portfolio is balanced but heavily levered to medical office demand. The single-digit growth rate is respectable for a REIT but offers limited operating leverage, and the sequential revenue gains have been incremental rather than explosive, implying the investment case rests more on cash flow stability and dividend coverage than on top-line acceleration. Profitability is thin and volatile, which is characteristic of a REIT carrying heavy depreciation. Q1 2026 net income was $193.63 million on a 25.72% net margin, a dramatic swing from the $117.12 million loss in Q3 2025 and the $113.97 million profit in Q4 2025, while the reported gross margin of -19.97% reflects accounting treatment of property costs rather than true economic deterioration. Operating margin of 19.28% and EBITDA of $576.94 million in Q1 2026 show the underlying property-level economics remain solid, with EBITDA margin of 76.62% underscoring the cash-generative nature of the asset base despite GAAP earnings noise. The balance sheet carries meaningful leverage but remains manageable for a REIT. Debt-to-equity stands at 1.39x with a current ratio of 1.09, and the company generated $1.18 billion in trailing free cash flow, yielding roughly 10.6% of the $11.19 billion market cap. Q1 2026 operating cash flow of $260.88 million comfortably covered the $211.99 million dividend, and the company retired $560.01 million of debt while funding $427.85 million of acquisitions, demonstrating access to capital and active portfolio management. Return on equity of just 0.95% and return on assets of 1.51% are low in absolute terms, but typical for capital-intensive REITs, and the 7.59% dividend yield remains the central pillar of the shareholder return proposition.
Quarterly Revenue
$752952000.0B
2026-03
Revenue YoY Growth
+7.1%
YoY Comparison
Gross Margin
-20.0%
Latest Quarter
Free Cash Flow
$1.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DOC Overvalued?
Because Healthpeak generated positive trailing net income, the PE ratio is the appropriate primary metric, though it must be interpreted with caution given REIT accounting distortions. The trailing PE stands at an extraordinary 160.8x against a forward PE of 139.2x, both far above any reasonable earnings-based benchmark, reflecting the depressed GAAP earnings base rather than a genuine growth premium. The modest narrowing from trailing to forward PE implies the market expects only marginal earnings improvement, and with a PEG ratio of -2.23, earnings-based valuation offers little analytical signal here; the price-to-book ratio of 1.49x and price-to-sales ratio of 3.97x are far more meaningful for this REIT. Relative to the broader real estate sector, Healthpeak's 1.49x price-to-book sits at a modest premium to book value, which is reasonable for a diversified healthcare landlord with stable cash flows, while its 7.59% dividend yield is well above the sector norm and reflects the market's discounting of payout sustainability. The EV/EBITDA multiple of 14.31x is elevated for a healthcare REIT, suggesting the market is capitalizing the portfolio's cash flows at a premium that may not be fully justified by the low single-digit growth rate. Historically, Healthpeak's price-to-book has ranged from roughly 1.25x in early 2024 to 2.99x in late 2021, placing the current 1.49x near the lower end of its multi-year band and close to the 1.46x recorded in Q1 2026. Its price-to-sales ratio of 3.97x compares favorably to historical readings of 15x to 40x in prior periods, though methodology differences complicate direct comparison. The stock is not expensive on asset-based measures, but the elevated EV/EBITDA and near-160x PE indicate that GAAP earnings recovery is essential for the valuation to normalize, and the market is currently pricing in a slow, uncertain path to that recovery.
PE
160.8x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 9x~96x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.7x
Enterprise Value Multiple
Investment Risk Disclosure
DOC faces significant financial and operational risks, primarily stemming from its high leverage and thin profitability. The debt-to-equity ratio of 1.39x is elevated for a REIT, and interest expense of $87.3 million in Q1 2026 represents a substantial fixed cost that could strain cash flows if revenue growth stalls. Additionally, the company's return on equity of just 0.95% and return on assets of 1.51% indicate inefficient capital deployment, and the volatile net income—swinging from a $117.1 million loss in Q3 2025 to a $193.6 million profit in Q1 2026—highlights earnings instability. With a payout ratio of only 11.9% of trailing earnings, the dividend appears safe, but the low earnings base means any operational setback could pressure the payout. Market and competitive risks include the potential for valuation compression given DOC's premium multiples. The stock trades at 160.8x trailing PE and 14.31x EV/EBITDA, which are high for a healthcare REIT with low single-digit growth, leaving little room for error. The beta of 0.989 suggests market-level volatility, but sector-specific headwinds such as rising interest rates could disproportionately impact REIT valuations. Recent analyst downgrades by Barclays and Morgan Stanley to Equal Weight reflect concerns about the sustainability of the recovery, and the wide analyst target range of $17 to $29 indicates significant disagreement. Competitive pressures in life science leasing, where demand is tied to biotech funding cycles, could further challenge growth. In a worst-case scenario, a combination of rising interest rates, weakening leasing demand, and earnings misses could drive DOC toward its 52-week low of $15.70, representing a 19.4% decline from the current price of $19.49. If the bear case materializes, the stock could fall to the analyst low target of $17.00, a 12.8% drop, or even lower if dividend sustainability concerns arise. The maximum drawdown over the past year was 18.53%, indicating that such a decline is within historical norms. Investors could lose approximately 19% from current levels in this adverse scenario, underscoring the importance of monitoring interest rate trends and leasing activity.
FAQ
The key risks include financial risks from high leverage, with a debt-to-equity ratio of 1.39x and interest expense consuming a significant portion of income. Operational risks stem from volatile earnings, as seen in the swing from a $117.1 million loss in Q3 2025 to a $193.6 million profit in Q1 2026. Market risks include valuation compression due to premium multiples and sensitivity to interest rates, given the beta of 0.989. Competitive risks involve potential weakness in life science leasing demand, which could impair revenue growth. Additionally, analyst downgrades and negative momentum pose near-term risks. Ranked by severity, financial and market risks are most critical, followed by operational and competitive risks.
The 12-month forecast for DOC includes a bull case with 25% probability targeting $25-29, a base case with 55% probability targeting $21-24, and a bear case with 20% probability targeting $15.70-17.00. The base case assumes steady revenue growth of 6% and stable interest rates, leading the stock to trade toward the analyst average target of $22.95. The bull case requires accelerating leasing demand and rate cuts, while the bear case involves a recession or rising rates. The most likely scenario is the base case, with the key assumption being no major deterioration in fundamentals. Investors should monitor earnings and interest rate trends to adjust expectations.
DOC appears overvalued on earnings-based metrics, with a trailing PE of 160.8x and forward PE of 139.2x, far above typical REIT levels. However, on an asset basis, its price-to-book ratio of 1.49x is near the lower end of its historical range, suggesting the stock is not expensive relative to its net asset value. The EV/EBITDA of 14.31x is elevated for a healthcare REIT with low single-digit growth. The market is pricing in a slow earnings recovery, and if that fails to materialize, the stock could face further downside. Overall, DOC is fairly valued to slightly overvalued, with the dividend yield providing some support.
DOC may be a good buy for income-focused investors, given its 7.59% dividend yield and analyst consensus target of $22.95, implying 17.7% upside. However, the stock trades at a premium valuation with a trailing PE of 160.8x and has recently underperformed the market, down 10.96% over three months. The risk-reward is balanced, with the dividend providing a cushion but limited near-term catalysts. Investors should consider their tolerance for volatility and interest rate risk. For those seeking high current income and willing to hold long-term, DOC could be suitable, but it may not be ideal for those seeking rapid capital appreciation.
DOC is more suitable for long-term investment, given its stable dividend yield of 7.59% and low beta of 0.989, which reduces volatility. The company's earnings visibility is moderate, with revenue growth of 7.12% year-over-year, but the recent negative momentum and premium valuation suggest short-term trading could be risky. A minimum holding period of 2-3 years is recommended to allow for earnings recovery and potential multiple expansion. Income investors may hold indefinitely for the dividend, while growth-oriented investors might seek better opportunities elsewhere. Short-term traders should be cautious due to the stock's recent underperformance and wide analyst target range.
